Form 4: NeuroPace CMO's Stock Withholding for Tax Obligations

NeuroPace's Chief Medical Officer, Martha Morrell, had 3,051 shares withheld by the company to cover tax obligations related to a restricted stock unit vesting.

Summary

• Martha Morrell, Chief Medical Officer of NeuroPace Inc. (NPCE), had 3,051 shares of common stock withheld by the company.
• This transaction occurred on November 20, 2025, at a price of $13.5 per share.
• The shares were withheld to satisfy tax withholding obligations associated with the vesting of a restricted stock unit award.
• Following this transaction, Ms. Morrell beneficially owns 80,429 shares of NeuroPace common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation and tax obligations, which is neutral in sentiment.

Positives

• The transaction indicates the vesting of a restricted stock unit award, suggesting continued compensation and retention of a key executive.

Negatives

• No direct negatives, as this is a routine tax-related transaction.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This routine insider transaction reflects standard executive compensation practices within the medical device or biotechnology industry, where restricted stock units are a common component of long-term incentive plans. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• The withholding of shares for tax purposes upon RSU vesting is a standard practice across publicly traded companies, including those in the medical technology sector.
• This transaction aligns with typical executive compensation structures and tax compliance procedures, similar to practices observed at companies like Medtronic, Boston Scientific, or Abbott Laboratories, which also utilize equity awards for executive incentives.

Stakeholder Impact

• Shareholders: Minimal direct impact, as it's a routine tax-related transaction for executive compensation. It confirms the vesting of equity for a key executive.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

NeuroPace, NPCE, Martha Morrell, Chief Medical Officer, Form 4, SEC filing, stock withholding, restricted stock units, RSU vesting, insider transaction, executive compensation